Daily Endocrinology Research Analysis
Three impactful endocrinology papers stood out today: a revised ESE guideline provides an updated, practical algorithm for managing aggressive pituitary tumors and carcinomas; real-world data show that switching children with X-linked hypophosphatemia to burosumab significantly improves lower-limb alignment versus active vitamin D/phosphate; and a mechanistic study suggests PHEX in the parathyroid contributes to phosphate sensing, potentially explaining hyperparathyroidism in XLH.
Summary
Three impactful endocrinology papers stood out today: a revised ESE guideline provides an updated, practical algorithm for managing aggressive pituitary tumors and carcinomas; real-world data show that switching children with X-linked hypophosphatemia to burosumab significantly improves lower-limb alignment versus active vitamin D/phosphate; and a mechanistic study suggests PHEX in the parathyroid contributes to phosphate sensing, potentially explaining hyperparathyroidism in XLH.
Research Themes
- Translational advances in rare phosphate-wasting disorders (XLH): from mechanism to therapy
- Updated multidisciplinary management of aggressive pituitary tumors and carcinomas
- Endocrine phosphate sensing: PHEX-mediated modulation of parathyroid PTH responses
Selected Articles
1. Switching from active vitamin D and phosphate supplementation to burosumab significantly corrects lower limb malalignment in pediatric X-linked hypophosphatemia.
In a real-world disease monitoring cohort, switching from active vitamin D/phosphate to burosumab led to significantly more improvements in mechanical femoral–tibial angle than continuing supplements, with an OR of 4.38 for limb improvement. Earlier initiation and lower baseline height Z-score predicted larger alignment gains.
Impact: This provides comparative, practice-informing evidence that burosumab not only improves biochemistry but also skeletal alignment outcomes, with timing of initiation influencing magnitude of benefit.
Clinical Implications: For pediatric XLH, consider earlier transition to burosumab to maximize limb alignment correction and potentially reduce need for orthopedic surgery; monitor radiographic mFTA to assess response.
Key Findings
- Switching to burosumab increased the proportion of limbs with improved mechanical femoral–tibial angle versus continuing active vitamin D/phosphate (p<0.023).
- Odds of limb improvement were significantly higher with burosumab (OR 4.38, 95% CI 1.09–17.50; p=0.0469).
- Younger age at burosumab initiation (p=0.001) and lower baseline height Z-score (p=0.006) were associated with greater mFTA Z-score change.
Methodological Strengths
- Real-world, longitudinal comparison within a disease monitoring program with standardized radiographic assessments to Year 3.
- Multivariate factor analysis across 24 attributes to identify predictors of alignment change.
Limitations
- Observational, non-randomized treatment allocation may introduce selection bias.
- Total sample size per treatment subgroup and potential confounders are not fully detailed in the abstract.
Future Directions: Prospective randomized trials to confirm skeletal alignment benefits, dose–timing optimization studies, and long-term functional outcomes and surgery avoidance metrics.
X-linked hypophosphatemia (XLH) is a rare disorder of renal phosphate wasting and dysregulated active vitamin D metabolism, ultimately presenting as rickets and osteomalacia, among other manifestations. Lower extremity deformity (genu valgum and/or varum) is frequent in this pediatric population. Despite prompt active vitamin D and phosphate supplementation (active D/Pi), many patients require corrective surgery for lower limb malformation. Burosumab has demonstrated improvements in lower limb malalignment in children with XLH in several studies. We expand on those reports by assessing mechanical femoral tibial angle (mFTA) change in patients enrolled in the XLH Disease Monitoring Program (DMP), (NCT03651505) to determine the impact of initiating burosumab treatment after a history of active D/Pi. Included patients had either switched from active D/Pi to burosumab treatment at the discretion of their treating physician or as part of a burosumab clinical trial, or remained on active D/Pi through Year 3 of the DMP. Year 3 radiographs were compared with baseline to assess mFTA change and gauge improvement. Additional multivariate factor analysis examined 24 attributes to determine which had the greatest association with mFTA change. Change in mFTA was assessed for each limb independently. A greater proportion of limbs of patients switching from active D/Pi to burosumab had improved mFTA compared with those remaining on active D/Pi (p < .023). Odds ratios comparing limbs that improved to those that did not showed that switching to burosumab yields a significantly greater chance of improvement than continuing active D/Pi (OR [95% CI]: 4.38 [1.09-17.50]; p = .0469). Factor analysis identified younger age at burosumab initiation (p = .001) and lower baseline height Z-score (p = .006) as being significantly associated with greater change in mFTA Z-score. This study shows that switching to burosumab significantly improves lower limb malalignment in children with XLH over benefits conferred by active D/Pi, with early burosumab initiation providing the greatest benefit.
2. Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.
This interdisciplinary update integrates new evidence (temozolomide, immune checkpoint inhibitors, bevacizumab) and the second ESE survey into a practical algorithm, and standardizes imaging/histopathology reporting for aggressive pituitary tumors and carcinomas. It also addresses molecular analysis and special circumstances like pregnancy.
Impact: Guidelines shape practice across centers; this update operationalizes emerging therapies and harmonizes reporting, likely improving identification and management of aggressive disease.
Clinical Implications: Adopt the algorithm for APT/PC workup and therapy sequencing (including temozolomide first-line for aggressive behavior, and consideration of ICIs/bevacizumab in selected cases); implement standardized imaging/histopathology reporting and consider molecular profiling.
Key Findings
- Provides a revised, practical algorithm for diagnosis and management of aggressive pituitary tumors and carcinomas.
- Incorporates new data supporting temozolomide, immune checkpoint inhibitors, and bevacizumab in selected settings.
- Proposes standardized imaging and histopathology reporting and discusses the role of molecular analysis; addresses special situations such as pregnancy.
Methodological Strengths
- International, interdisciplinary guideline leveraging new survey data and literature synthesis.
- Translates heterogeneous evidence into a structured, actionable algorithm and standardized reporting framework.
Limitations
- Many recommendations rely on non-randomized data and small series; overall evidence quality varies.
- Guideline impact depends on implementation and local resources; prospective validation is limited.
Future Directions: Prospective multicenter registries and trials to evaluate sequencing of temozolomide, ICIs, and anti-VEGF strategies; validation of standardized reporting and molecular markers for prediction.
Pituitary tumours, originating from endocrine cells of the anterior pituitary, are quite common, and in most cases well-controlled by surgery or medical treatment. However, a small subset of pituitary tumours presents with multiple local recurrences or tumour progression despite combined surgical, medical or radiotherapeutic treatment. These are known as aggressive pituitary tumours (APT); also called aggressive pituitary neuroendocrine tumours (PitNETs); or, in the rare case of metastases, pituitary carcinomas (PC) or metastatic PitNETs. Early identification of APT is challenging but is of major clinical importance as they are associated with an increased morbidity and mortality even in the absence of metastases. Here, we provide a revision of the first international, interdisciplinary European Society of Endocrinology (ESE) clinical practice guideline on APTs and PC (2018). Since publication of the 2018 guideline, results from the second ESE survey on APT and PC were published, and more data on APT treatment, including temozolomide, immune checkpoint inhibitors and bevacizumab, emerged. These data are reviewed in this guideline and translated into a practical algorithm to guide APT and PC management. Furthermore, standardized reporting of imaging and histopathological investigations of these tumours is proposed, and the role of molecular analysis is discussed. Last, a section is dedicated to special circumstances such as APT in pregnancy.
3. PHEX protein in the parathyroid gland contributes to phosphate sensing.
Compared with tumor-induced osteomalacia, patients with XLH exhibited a markedly steeper iPTH rise per increment in serum phosphate 1 hour after oral phosphate loading, despite stable calcium. This suggests that PHEX in the parathyroid may set the phosphate-sensing threshold and modulate acute PTH secretion.
Impact: This is a mechanistic, human evidence indicating a novel role of PHEX in parathyroid phosphate sensing, offering a plausible explanation for frequent secondary/tertiary hyperparathyroidism in XLH and informing management of phosphate therapy.
Clinical Implications: In XLH, aggressive phosphate loading may provoke exaggerated PTH responses; clinicians should monitor PTH closely and consider strategies (e.g., calcimimetics or tailoring phosphate dosing) to mitigate secondary/tertiary hyperparathyroidism risk.
Key Findings
- After oral phosphate loading (300–1,500 mg), serum phosphate rose while corrected calcium remained stable.
- The iPTH versus serum phosphate slope was significantly higher in XLH (median 41.4) than in TIO (7.1), p=0.034.
- Findings support a role for parathyroid PHEX in phosphate-sensing thresholds and acute PTH secretion.
Methodological Strengths
- Direct physiological comparison under controlled oral phosphate loading with quantitative slope analysis.
- Use of TIO as a disease control group with elevated FGF23 but intact PHEX, enabling mechanistic inference.
Limitations
- Small sample size (6 XLH, 13 TIO) and retrospective design limit generalizability.
- Short-term (1-hour) responses only; no long-term PTH dynamics or clinical outcomes assessed.
Future Directions: Prospective studies to map PTH kinetics across wider phosphate doses and to test modulators (e.g., calcimimetics) in XLH; molecular studies of PHEX expression/function in human parathyroid tissue.
CONTEXT: Loss-of-function variants in the PHEX gene cause X-linked hypophosphatemia (XLH) with inappropriate secretion of fibroblast growth factor (FGF) 23. The PHEX protein is therefore predicted to be involved in the phosphate (Pi)-sensing mechanism in mature osteocytes. The parathyroid glands sense short-term fluctuations in serum Pi levels and secrete parathyroid hormone (PTH) accordingly. However, the precise mechanisms for Pi sensing in the parathyroid gland have not been elucidated. OBJECTIVE: To clarify the involvement of PHEX in phosphate sensing in the parathyroid glands, PTH reactions after Pi loading were retrospectively compared between patients with XLH and those with tumor-induced osteomalacia (TIO). METHODS: Serum Pi, intact PTH (iPTH) and albumin-corrected serum calcium (cCa) levels at 1 hour after oral phosphate administration at doses ranging from 300 mg to 1,500 mg were analyzed. The trend of iPTH in each participant was compared between XLH and TIO. RESULTS: Six XLH patients and 13 TIO patients were included. The serum Pi level significantly increased after the oral Pi load, whereas the serum cCa level was stable. The slope of the scatter plot of iPTH (pg/mL) versus Pi (mg/dL) after the oral Pi load for each patient was 41.4 (median) in XLH, which was significantly greater than the 7.1 in TIO (p = 0.034). CONCLUSION: iPTH increased in accordance with Pi levels, with a greater slope observed in XLH than in TIO after oral Pi loading. This finding suggests that PHEX in the parathyroid glands might also determine the serum Pi-sensing threshold and mediate PTH secretion in the case of abrupt fluctuations in serum Pi levels, which may explain the high prevalence of secondary and tertiary hyperparathyroidism in patients with XLH.